Merck opens €55m Irish plants supporting downstream consumables business

By Dan Stanton contact

- Last updated on GMT


Related tags: Biotechnology

Germany’s Merck has opened a chromatography media facility as part of a €55m investment in Ireland supporting growing demand for its Protein A resin.

The total investment was spread across Merck’s site in Carrigtwohill, Cork, and sees the firm add a speciality membrane facility along with the chromatography media plant to its life science consumables business.

According to the firm, the membrane plant will be the location of choice for the development and manufacture of all future Merck Life Science membrane products, while the media plant will provide the site with advanced technological capabilities, becoming the main supplier for Merck’s chromatography business including the Protein A capture media ProSep.

“ProSep media has been used for more than 25 years in purification of monoclonal antibodies. The business has grown with the advent of approval of monoclonal antibody therapies within the biopharmaceutical industry,” ​a spokesperson from the firm told us.

“The Cork investment signifies Merck Life Science’s continued expectations for continued growth of monoclonal therapies and products like ProSep to support them.”

Merck is not the only firm to have expanded its capacity for downstream media. Protein A resin manufacturer Purolite recently announced plans for a new 100,000L facility in Wales​, UK to support its media product Praesto, while GE Healthcare expanded a cell culture site in Austria​ to support its downstream consumables business.

“Downstream processing end users continue to push trends like process intensification, single-use and continuous processing,”​ Merck said.

“Downstream processing products focus on eliminating bottlenecks and improving economic. This includes high capacity incompressible protein A resins which lead to an efficient operation of continuous chromatography unit operations.”

The facilities officially opened last week.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more